GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...
The following is a summary of “Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a ...
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback